Skip to main content
Download PDF
Download ePub

A systematic study on the treatment of hepatitis B-related hepatocellular carcinoma with drugs based on bioinformatics and key target reverse network pharmacology and experimental verification

Infectious Agents and Cancer volume 18, Article number: 41 (2023) Cite this article

Abstract

Background

Chronic hepatitis B virus (HBV) infection is the major etiology of hepatocellular carcinoma (HCC). However, the mechanism of hepatitis B-related hepatocellular carcinoma (HBV-related HCC) is still unclear. Therefore, understanding the pathogenesis and searching for drugs to treat HBV-related HCC was an effective strategy to treat this disease.

Purpose

Bioinformatics was used to predict the potential targets of HBV-related HCC. The reverse network pharmacology of key targets was used to analyze the clinical drugs, traditional Chinese medicine (TCM) and small molecules of TCM in the treatment of HBV-related HCC.

Methods

In this study, three microarray datasets totally containing 330 tumoral samples and 297 normal samples were selected from the GEO database. These microarray datasets were used to screen DEGs. And the expression profile and survival of 6 key genes were analyzed. In addition, Comparative Toxicogenomics Database and Coremine Medical database were used to enrich clinical drugs and TCM of HBV-related HCC by the 6 key targets. Then the obtained TCM were classified based on the Chinese Pharmacopoeia. Among these top 6 key genes, CDK1 and CCNB1 had the most connection nodes and the highest degree and were the most significantly expressed. In general, CDK1 and CCNB1 tend to form a complex, which is conducive to cell mitosis. Hence, this study mainly studied CDK1 and CCNB1. HERB database was used to predict small molecules TCM. The inhibition effect of quercetin, celastrol and cantharidin on HepG2.2.15 cells and Hep3B cells was verified by CCK8 experiment. The effects of quercetin, celastrol and cantharidin on CDK1 and CCNB1 of HepG2.2.15 cells and Hep3B cells were determined by Western Blot.

Results

In short, 272 DEGs (53 upregulated and 219 downregulated) were identified. Among these DEGs, 6 key genes with high degree were identified, which were AURKA, BIRC5, CCNB1, CDK1, CDKN3 and TYMS. Kaplan–Meier plotter analysis showed that higher expression levels of AURKA, BIRC5, CCNB1, CDK1, CDKN3 and TYMS were associated with poor OS. According to the first 6 key targets, a variety of drugs and TCM were identified. These results showed that clinical drugs included targeted drugs, such as sorafenib, palbociclib and Dasatinib. and chemotherapy drugs, such as cisplatin and doxorubicin. TCM, such as the TCM flavor was mainly warm and bitter, and the main meridians were liver and lung. Small molecules of TCM included flavonoids, terpenoids, alkaloids and glycosides, such as quercetin, celastrol, cantharidin, hesperidin, silymarin, casticin, berberine and ursolic acid, which have great potential in anti-HBV-related HCC. For molecular docking of chemical components, the molecules with higher scores were flavonoids, alkaloids, etc. Three representative types of TCM small molecules were verified respectively, and it was found that quercetin, celastrol and cantharidin inhibited the proliferation of HepG2.2.15 cells and Hep3B cells along concentration gradient. Quercetin, celastrol and cantharidin decreased CDK1 expression in HepG2.2.15 and Hep3B cells, but for CCNB1, only cantharidin decreased CCNB1 expression in the two strains of cells.

Conclusion

In conclusion, AURKA, BIRC5, CCNB1, CDK1, CDKN3 and TYMS could be potential targets for the diagnosis and prognosis of HBV-related HCC. Clinical drugs include chemotherapeutic and targeted drug, traditional Chinese medicine is mainly bitter and warm TCM. Small molecular of TCM including flavonoids, terpenoids and glycosides and alkaloids, which have great potential in anti-HBV-related HCC. This study provides potential therapeutic targets and novel strategies for the treatment of HBV-related HCC.

Introduction

Hepatocellular carcinoma (HCC) was the third leading cause of cancer-associated mortality worldwide [1]. Major risk factors for HCC were chronic hepatitis B virus infection, alcoholic liver disease and cirrhosis. The main cause of liver cancer was persistent hepatitis B virus (HBV) infection, which had accounted for more than half of liver cancer cases [2,3,4]. Epigenetic regulation of HBV protein to tumor suppressor genes was involved in the development and progression of hepatitis B-related hepatocellular carcinoma (HBV-related HCC) [5]. However, the mechanism of HBV-related HCC is still unclear. Therefore, in order to improve the survival rate of patients, it is urgent to screen out biomarkers for the diagnosis, prognosis and treatment of HBV-related HCC.

Microarrays have been widely used for molecular diagnosis and for the discovery of new cancer biomarkers, and these techniques were excellent choices for analyzing large gene expression datasets in order to understand the pathogenesis of HBV-related HCC. Many cancer-related databases, such as Gene Expression Synthesis (GEO) and gene expression profile Interaction Analysis (GEPIA), have been developed to analyze the expression of tumor-related genes. Moreover, Kaplan–Meier plotter has been used to analyze gene-related prognoses, contributing to the diagnosis and treatment of cancer.

In addition, the Comparative Toxicogenomics Database (CTD) [6] is an online database that provides information on the interactions between gene products and chemotherapy drugs and diseases. 6 key genes screened from three datasets in GEO database were used for reverse network pharmacology research. CTD, Coremine Medical database and HERB database were used to identified drugs, traditional Chinese medicine (TCM) and small molecules of TCM, respectively. Then, reverse network pharmacology used a variety of public databases for initial disease target selection. Based on the selected targets, effective drugs for a certain disease were explored [7, 8].

Clinical targeted drugs include sorafenib, palbociclib and Dasatinib. And chemotherapy drugs, such as DNA-targeting cisplatin and doxorubicin, are widely used to treat a variety of cancers, including HCC [9]. These clinical drugs benefit many patients. In China, TCM played an important role in treating diseases. TCM had the characteristics of multi-component and multi-target in the treatment of HCC. Therefore, exploring TCM as an effective and low-toxicity anti-cancer drug provided a broad prospect for the prevention and treatment of HCC [10]. In addition, many natural products, such as flavonoids, terpenoids and glycosides and alkaloids, are being evaluated clinically for liver cancer. These compounds inhibit the formation of liver cancer by affecting anti-inflammatory, antioxidant, anti-angiogenesis and anti-metastasis activities [11, 12]. This specific method of finding therapeutic drugs through targets enabled us to find drugs closely related to diseases, which was conducive to faster large-scale drug screening. The aim of this study was to screen out the potential targets of HBV-related HCC, as well as TCM and chemical components for its treatment by integrated analysis, so as to provide scientific reference for revealing the mechanism of HBV-related HCC and a reliable theoretical basis for the of anti-HBV-related HCC development.

Materials and methods

Microarray data

These three profiles GSE47197 [13], GSE84402 [14] and GSE14520 [15] were obtained from the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/). Data from GSE47197 was based on GPL16699 platform and included 61 HBV-related HCC tissues and 63 normal tissues. Data from GSE84402 was based on GPL4133 platform and included 14 HBV-related HCC tissues and 14 normal tissues. Data from GSE14520 was based on GPL3921 platform and included 225 HBV-related HCC tissues and 220 normal tissues.

Screening for DEGs

The identification of differentially expressed genes (DEGs) between HBV-related HCC and normal tissues was performed in GEO2R (https://www.ncbi.nlm.nih.gov/geo/geo2r/) [16]. As a cutoff criterion, |log FC|> 1.0 and adjusted P‑value (adjust‑P) < 0.05 were used to identified genes and visualized by volcano plots (http://www.bioinformatics.com.cn/). These three profiles were visualized using the Venn diagram webtool (bioinformatics. psb.ugent.be/webtools/Venn/).

PPI network and key genes analysis

Search Tool for the Retrieval of Interacting Genes/Proteins (STRING version 11.5) (https://string-db.org/) [17] online database was used to constructed protein-protein interaction (PPI) network. Then, the PPI network was visualized by Cytoscape version 3.8.2 software (https://cytoscape.org/). In addition, the key subnetwork and degree of each protein node was evaluated by MCODE and Cytohubba, respectively. The top 6 genes (AURKA, BIRC5, CCNB1, CDK1, CDKN3 and TYMS) were identified as the key genes.

Verification of the key genes in GEPIA and UALCAN database

Gene Expression Profiling Interactive Analysis (GEPIA) (http://gepia.cancer-pku.cn/) [18], a cancer big data analysis website, was used to analyze differential expression from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) portal. The cut-off criteria of |log2FC|= 1 and P-value ≤ 0.01 were considered statistically significant. UALCAN(http://ualcan.path.uab.edu) [19], a user friendly interactive network resources, was used to analyze cancer transcriptome data (TCGA and MET500 transcriptome sequencing). Therefore, we analyzed the different stages of 6 key genes.

Protein expressions of key genes in the HPA database

The Human Protein Atlas (HPA) version 21.0 website (https://www.proteinatlas.org/) [20] provided researchers with a wealth of proteomic data on human tissues and cells. HPA database was used to validate the immunohistochemistry of 5 key genes in HCC tissues and normal tissues. However, image of CDKN3 was not found.

Survival analysis of key genes

Kaplan-Meier plotter (https://kmplot.com/analysis/) [21] was performed overall survival (OS) analysis of 6 key genes. Kaplan-Meier plotter (https://kmplot.com/analysis/) predicted survival time, providing a comparison of survival rates between patients with low and high expression levels of a particular gene, and calculating log‑rank P‑value and hazard ratios (HR) with 95% confidence intervals. We performed the survival curves of 6 key genes at 48 months to prevent crossover.

Drug-gene interaction network analysis

The Comparative Toxico genomics Database [6] (CTD, http://ctdbase.org/) is an online database that provides information on the interactions between gene products and chemotherapy drugs and diseases. It was used to construct chemotherapeutic drug-gene interaction networks [22]. And was visualized using Cytoscape software 3.8.2.

Analysis of corresponding chemical components of key targets

HERB (http://herb.ac.cn/) database [23] gathered and reanalyzed 1,037 high throughput sequencing experiments that were treated by herbs/ingredients, which was used to analyze the components corresponding to key targets, including the components verified by literature and predicted by multiple databases.

Key target prediction of traditional Chinese medicine and its classification and characteristics

Coremine Medical database [ 24] (http://www.coremine.com/medical/?locale=zh_CN#search?ids=518629&tt=7679&org=hs&i=518629) was a medical information retrieval platform. Top 6 genes related to HBV-related HCC were input into Coremine Medical database for TCM screening. Then the obtained TCM were imported into TCMSP database. Finally, the mainly TCM were obtained. The regularity of TCM treatment of HBV-related HCC was obtained by frequency analysis. Various properties such as channel tropism, flavor, and property were investigated and were visualized using bioinformatics tools (http://www.bioinformatics.com.cn/).

Molecular docking

The structure of small molecule was downloaded from Pubchem (https://pubchem.ncbi.nlm.nih.gov/) database, and the structure of AURKA, BIRC5, CCNB1, CDK1, CDKN3 and TYMS were downloaded from PDB (https://www.rcsb.org/) database. Later, the target proteins were imported into Auto Dock Tools 1.5.6 for hydrogenation, charge calculation, and non-polar hydrogen combination, and then the result was stored in PDBQT format.

Cell line and drug treatment

HepG2.2.15 cells and Hep3B2.1-7 (Hep3B) cells were purchased from iCell Bioscience Inc. These cells were cultured in Cell specific culture-medium (icell-h091-001b) at 37 ℃ and 5% CO2 in an atmosphere of 100% humidity. Quercetin (Lot. # 131,328) and Celastrol (Lot. # 145,154) were purchased from TargetMol Chemicals Inc. Cantharidin (Lot. # GN10058) was purchased from GlpBio Technology. HepG2.2.15 and Hep3B cells were treated with quercetin, celastrol and cantharidin for 24 h or 48 h, respectively.

Cell viability assay

HepG2.2.15 cells and Hep3B cells were seeded in 96-well plates (5 × 104 cells/well). HepG2.2.15 cells were treated with quercetin (100 μM, 200 μM, 300 μM, 400 μM), celastrol (0.1 μM, 0.5 μM, 1 μM, 2 μM), cantharidin (3 μM, 6 μM, 9 μM, 12 μM) at different concentration for 24 h, and 48 h, respectively. Hep3B cells were treated with quercetin (100 μM, 200 μM, 300 μM, 400 μM), celastrol (0.1 μM, 0.5 μM, 1 μM, 2 μM), cantharidin (1 μM, 2 μM, 3 μM, 4 μM) at different concentration for 24 h, and 48 h, respectively. Cell viability was measured using Cell Counting Kit-8 (CCK-8, Cat. # BS350B, Biosharp) according to manufacturer's protocol. Finally, optical density (OD) was monitored at 450 nm. IC50 values were obtained from the cytotoxicity curves using the ELx800 software.

Western blot analysis

HepG2.2.15 cells and Hep3B cells were seeded in 6-well plates (1 × 105 cells/well) and treated as described above. In brief, they were washed in PBS, and the cells were directly lysed in a SDS sample buffer. Protein concentration was determined by a BCA method (P0013, Beyotime Biotechnology.). The primary antibodies were rabbit anti-CDK1 polyclonal antibody (Cat. # CY5061, Abways, diluted to 1:2000), anti-CCNB1 polyclonal antibody (Cat. # CY5378, Abways, diluted to 1:2000), and β-actin antibody (Cat. # AC026, abclonal, diluted to 1:50,000). The secondary antibodies were goat anti-rabbit (S0001, affbiotech, diluted by 1:5000). The results were analyzed using SPSS 17.0 software (SPSS, Chicago, IL).

Statistical analysis

Using GEO2R, the adjusted P values of genes from the GEO were calculated. Genes with an adjusted P value < 0.05 was regarded as statistically significant. For the Kaplan‐Meier plotter, TIMER and GEPIA analysis, hazard ratios (HR) with 95% confidence intervals and log-rank P values were calculated. P value < 0.05 was taken as a statistically significant difference.

Results

Identification of DEGs and PPI network construction

Gene expression profiles of HBV-related HCC and normal liver tissues were obtained from GSE47197, GSE84402 and GSE14520. The results showed that 679, 1220 and 1095 DEGs were identified in GSE47197, GSE84402 and GSE14520, respectively. And the data of each gene expression profile were visualized by volcano plot (Fig. 1A). Subsequently, 53 overlapping upregulated genes and 219 overlapping downregulated genes were screened using Venn online (Fig. 1B). The PPI network was performed via the STRING database and was visualized Cytoscape software, including 247 nodes and 1652 edges. Green and red circulars indicated downregulated and upregulated genes, respectively (Fig. 1C). Then, MCODE analysis was used to detect the most important modules of PPI network. The higher the connection value of the node was, the higher the degree of network connection was, and the greater the correlation degree with disease was (Fig. 1D). The 6 key genes with high degree in HBV-related HCC, including AURKA, BIRC5, CCNB1, CDK1, CDKN3 and TYMS were identified (Fig. 1E).

Fig. 1
figure 1

Volcano plots and Venn diagrams of DEGs selected from three datasets. A. Volcano plots of DEGs from GSE47197, GSE84402 and GSE14520 datasets. The red dots and green dots were up-regulated and down-regulated DEGs. B. Venn diagram of upregulated (left) and downregulated (right) DEGs based on the three datasets, including 53 upregulated genes and 219 downregulated genes. C. The PPI network was constructed using STRING and visualized by Cytoscape. The red and green circulars represented up and down, respectively. D. The key modules were identified using the MCODE plugin of Cytoscape. E. The 6 key genes were screened in the PPI network by Cytohubba plugin of Cytoscape based on degree. These key genes were displayed from red (high degree value) to yellow (low degree value)

Full size image

Abnormal expression of 6 key genes in HBV-related HCC

Further, TIMER database was used to analysis. To confirm differential expression at the transcriptional level, the expression levels of 6 key genes were performed using GEPIA database. The results revealed that AURKA, BIRC5, CCNB1, CDK1, CDKN3 and TYMS were significantly upregulated in tumor tissues (Fig. 2A).

Fig. 2
figure 2

Abnormal expression of 6 key genes in HBV-related HCC. A. 6 key genes were more highly expressed in liver cancer tissues compared with those in the normal tissues in GEPIA database. The red and gray boxes represent cancer and normal tissues, respectively. B. The stage of (a) AURKA, (b) BIRC5, (c) CCNB1, (d) CDK1, (e) CDKN3 and (f) TYMS using UALCAN database. C. The immunohistochemical images of (a) AURKA, (b) BIRC5, (c) CCNB1, (d) CDK1, (e) TYMS in liver and HCC tissues using the HPA database

Full size image

The results showed that these 6 genes expression in HBV-related HCC tissues was higher than that in normal tissues, based on different pathological stages (Fig. 2B). Therefore, the expression levels of AURKA, BIRC5, CCNB1, CDK1, CDKN3 and TYMS served as diagnostic markers for liver cancer patients. In addition, overexpression of these 6 key genes was also associated with advanced pathological stage. Therefore, these results suggested that the expression of these 6 key genes played a significant role in the development of HBV-related HCC.

Subsequently, using the HPA database, the protein expression levels of 6 key genes were analyzed. Immunohistochemistry staining of HPA database showed that except CDKN3 was not found, AURKA, BIRC5, CCNB1, CDK1 and TYMS proteins were not or low expressed in normal liver tissues, while low (BIRC5), medium (CCNB1, CDK1 and TYMS) and high expression (AURKA) were shown in HBV-related HCC tissues (Fig. 2C).

Kaplan–Meier survival analysis of 6 key genes

To further illustrate whether 6 key genes were potentially prognostic markers for HBV-related HCC, OS was analyzed using Kaplan–Meier plotter (http://kmplot.com/analysis/). AURKA [hazard ratio(HR) = 1.97(1.36-2.85), log-rank P = 0.00024], BIRC5 [hazard ratio(HR) = 2.67(1.85-3.86), log-rank P = 5.2e-08], CCNB1 [hazard ratio(HR) = 2.42(1.66-3.51), log-rank P = 1.7e-06], CDK1 [hazard ratio(HR) = 2.3(1.59-3.34), log-rank P = 5.8e-06], CDKN3 [hazard ratio(HR) = 2.35(1.4-3.94), log-rank P = 0.00081] and TYMS [hazard ratio(HR) = 2.08(1.44-3), log-rank P = 6.8e-05] were highly expressed and associated with poor OS time (Fig. 3). Multiple databases showed that AURKA, BIRC5, CCNB1, CDK1, CDKN3 and TYMS could be prognostic markers for HBV-related HCC.

Fig. 3
figure 3

Survival analysis of 6 key genes (A) AURKA, (B) BIRC5, (C) CCNB1, (D) CDK1, (E) CDKN3 and (F) TYMS

Full size image

Prediction of clinical drug use and key target action by CTD database

Subsequently, several drugs were found to affect HBV-related HCC, a drug-gene PPI network was constructed using CTD database. The result showed that all drugs affected the expression levels of 6 key genes (AURKA, BIRC5, CCNB1, CDK1, CDKN3 and TYMS), but only Topotecan, Palbociclib, and Azathioprine reduced the expression levels of the 6 key genes. Interestingly, cisplatin had both promoting and inhibiting effects on 6 key genes. Targeted drugs include sorafenib, Dasatinib, Palbociclib, etc. Sorafenib inhibited BIRC5, CCNB1 and CDK1; Dasatinib inhibited AURKA and BIRC5; palbociclib inhibited AURKA, BIRC5, CCNB1, CDK1, CDKN3 and TYMS expression (Fig. 4).

Fig. 4
figure 4

The drug-gene interaction network of chemotherapeutic drugs and 6 key genes, (A) AURKA, (B) BIRC5, (C) CCNB1, (D) CDK1, (E) CDKN3 and (F) TYMS, was constructed using CTD database

Full size image

Meridian tropisms, tastes and properties of TCM against HBV-related HCC

We not only focus on target screening, but also combined with the corresponding herbs. The result showed that a total of 243 herbs were enriched by reverse enrichment of 6 key targets. To evaluate the reliability of the final results, the TCM recommended in the Guidelines for the Diagnosis and Treatment of primary liver Cancer (2022 edition) and the Clinical Guidelines for the Diagnosis and Treatment of chronic Hepatitis B (2018 edition) were summarized. After removing duplicates, 122 TCM were listed in the two guidelines. After comparison, 39 out of 122 herbs (almost 32%) were included in the 243 herbs, indicating that TCM produced by target-TCM reverse network pharmacology were not out of clinical practice. Among these 243 kinds of TCM, 136 were included in the Chinese Pharmacopoeia (2020 edition). Based on the results of frequency analysis, the medication rules of 136 herbs in the Chinese Pharmacopoeia (2020 edition) were summarized. In TCM, the nature of herbal medicine referred to its efficacy, divided into cold, cool, even, hot, and warm. The nature of TCM was the basis of its analysis and clinical application. As shown in the Fig. 5A, the main characters of 136 kinds of TCM were warm (32.35%), followed by cold (24.26%), and the total proportion of these two drugs accounted for more than half of all TCM. According to the theory of TCM, warm herbs had the effect of warming and nourishing qi and dispelling evil spirits. Secondly, cold herbs had scavenging and inhibiting effects [25].

Fig. 5
figure 5

Properties, tastes, and meridian tropisms of TCM against HBV-related HCC. A. Properties of herbs against HBV-associated HCC. B. Tastes of herbs against HBV-associated HCC. C. Meridian tropism of herbs against HBV-associated HCC

Full size image

Subsequently, we analyzed five flavors: pungent, sweet, sour, bitter and salty. The taste of the herb was mainly bitter, and then pungent (Fig. 5B). Bitter taste had the effect of clearing moisture and reducing fire, while pungent herb had the effect of dispersing outward and upward. Bitter medicine combined with pungent removed blood stasis. This improved blood circulation and relieve pain [25].

The theory of meridian tropism played an important role in clinical of TCM. The frequency of meridian return of TCM could be classified and determined by fan-shaped chart. From the meridional aspect, half of TCM was liver meridian, which was consistent with the disease areas of HBV-related HCC. The second meridian was the lung meridian (Fig. 5C). The liver was responsible for regulation and promotion. The lung was responsible for purification and descent [26]. The two organs complement each other to coordinate qi, blood and body fluid, and restore non-pathological state [27]. Our results also found that therapeutic effects were predominant for the liver, lung, spleen, and kidney, reflecting that TCM was holistic.

Key target reverse prediction of small molecule of TCM

Subsequently, the corresponding chemical components of 6 key targets were analyzed, including the chemical components verified by literature and the chemical components predicted by multiple databases (Table 1). The result indicated that 6 key targets of HBV-related HCC were identified in 115 TCM chemical components. A target-components PPI network was constructed, including 121 nodes and 196 edges (Fig. 6A). Red circles indicated targets and blue diamonds indicated chemical components. The edge indicated the interaction between the target and the chemical components. The larger the node, the greater the connectivity.

Table 1 In the Herb database, the components corresponding to key targets
Full size table
Fig. 6
figure 6

Key target reverse prediction of small molecule of TCM. A Target-component PPI network. Red circles represented target and blue diamonds represented component. B. Heat map of docking results between 105 chemical components (X-axis) and 6 targets (Y-axis). Blue to red indicates the docking score from small to large.

Full size image

Molecular docking could predict binding modes of small molecules of TCM with target proteins and predict molecular interactions. Taking into account the 3D structures not available in the PDB database, docking studies were conducted on 6 targets and 105 components. The average binding energy of 630 receptor-ligand docking results was about − 6.61 kcal/mol, indicating that these 105 chemical components had good binding affinity with 6 targets (Fig. 6B) (Table 2). The docking energy scores of 59 kinds of small molecules of TCM with 6 targets were greater than − 6.0 kcal/mol, mainly including flavonoids, glycosides and alkaloids and terpenoids, etc. Representative components of the three categories include quercetin, celastrol and cantharidin. Three kinds of small molecules were verified by experiments.

Table 2 Molecular docking binding energy results (kcal/mol)
Full size table

Effects of quercetin, celastrol and cantharidin on cellular viability

We further used in vitro experiments to verify the effects of three drugs on two HBV-associated hepatoma cell lines, HepG2.2.15 and Hep3B. HepG2.2.15 and Hep3B cells were treated with quercetin, celastrol and cantharidin for 24 and 48 h, respectively. The results showed that quercetin, celastrol and cantharidin inhibited proliferation of HepG2.2.15 and Hep3B cells, respectively. The IC50 values of quercetin, celastrol and cantharidin in HepG2.2.15 cells were 323.29 μM, 1.24 μM and 5.84 μM at 24 h, respectively (Fig. 7A, B). The IC50 values of quercetin, celastrol and cantharidin in Hep3B cells were 165.81 μM, 0.86 μM and 2.14 μM at 24 h, respectively (Fig. 7A, B). Therefore, these concentrations were selected as the intervention concentrations of quercetin, celastrol and cantharidin in subsequent experiments.

Fig. 7
figure 7

Effects of quercetin, celastrol and cantharidin on cellular viability. A. HepG2.2.15 and Hep3B cells treated with quercetin, celastrol and cantharidin at different concentrations. B. CCK8 was used to detect the cell viability effect of quercetin, celastrol and cantharidin on HepG2.2.15 and Hep3B cells

Full size image

Quercetin, celastrol and cantharidin decreased the expression of CDK1

Among these top 6 key genes, CDK1 and CCNB1 had the most connection nodes and the highest degree and were therefore, the most significantly expressed. In general, CDK1 and CCNB1 tend to form a complex, which is conducive to cell mitosis [28]. In addition, CDK1 and CCNB1, as cell cycle key proteins, are involved in the development of HBV-related HCC [29]. Hence, we selected two key targets (CDK1 and CCNB1) for further experimental verification. We also selected quercetin, celastrol and cantharidin at the most suitable IC50 concentration for intervention in HepG2.2.15 and Hep3B cells. The results indicated that quercetin, celastrol and cantharidin reduced the expression of CDK1 in HepG2.2.15 and Hep3B cells, respectively (Fig. 8A). Moreover, cantharidin also induced down-regulation of CCNB1 expression in HepG2.2.15 and Hep3B cells, but for CCNB1, only cantharidin decreased CCNB1 expression in the two strains of cells (Fig. 8B).

Fig. 8
figure 8

Effects of quercetin, celastrol and cantharidin on the expression of CDK1 and CCNB1. A. Effects of quercetin, celastrol and cantharidin on the expression of CDK1 and CCNB1 in HepG2215 cells. B. Effects of quercetin, celastrol and cantharidin on the expression of CDK1 and CCNB1 in Hep3B cells

Full size image

Discussion

HBV-related HCC remains one of the major cancers worldwide and has a serious economic impact on healthcare systems. It is important to develop effective diagnosis and treatment strategies and to understand the molecular mechanism of HCC caused by HBV infection.

In this study, three profile datasets were used to identify the DEGs using bioinformatic techniques. We identified a total of 53 upregulated DEGs and 219 downregulated DEGs. Therefore, screening DEGs played an important role in the diagnosis and prognosis of HBV-related HCC. To investigate the interaction of DEGs, PPI network was established and 6 key genes were identified, namely AURKA, BIRC5, CCNB1, CDK1, CDKN3 and TYMS. Moreover, high expression of AURKA, BIRC5, CCNB1, CDK1, CDKN3 and TYMS was associated with poor prognosis in patients with HBV-related HCC. All of the above analyses indicated that CDK1 and CCNB1 might be the most critical targets in HBV-related HCC.

Cyclin‑dependent kinase 1(CDK1), a member of the Ser/Thr protein kinase family, was the most critical cell cycle element for cell proliferation and organ development [30]. G2/mitotic-specific cyclin-B1 (CCNB1) was a major activator of CDK1 [31]. Studies showed that HBV activated CCNB1-CDK1 kinase in HCC cells in vitro [32]. CCNB1 and CDK1 were upregulated in HCC tissues of HBV-positive patients [33], and overexpression of CCNB1 and CDK1 was associated with poor prognosis [34]. In our study, CDK1 and CCNB1 were upregulated and high expression of CDK1 and CCNB1 were associated with poor prognosis in patients with HBV-related HCC. Therefore, we also focused on the verification of CDK1 and CCNB1 in the subsequent experimental verification.

In addition, other targets also play key roles in the development of HBV-related HCC. Aurora kinase A (AURKA) was involved in regulating the G2/M cell cycle and an important predictor of early HCC development [35]. AURKA was up-regulated in HCC tissues and correlated with pathological stage and distant metastasis. Silencing AURKA inhibited radiation-enhanced hepatocarcinoma cell invasion [36]. AURKA lle31Phe enhanced the predisposition of HBV-infected individuals to develop liver cancer [37, 38]. In this study, we found that AURKA was upregulated in many databases. Baculoviral IAP repeat-containing protein 5 (BIRC5) was upregulated in liver cancer. High expression of BIRC5 was associated with poor OS time. Studies showed that OCT4 upregulated the expression of BIRC5 and CCND1 by increasing the promoter activity of BIRC5 and CCND1, promoting HCC cells proliferation [39, 40]. In addition, Thymidylate synthase (TYMS) was an oncogene that regulates the cell cycle. TYMS was associated with HCC metastasis. The silencing of TYMS significantly inhibited the growth and invasion of HCC cells [41]. Our study also found that TYMS was upregulated in HBV-related HCC tissues. Thus, we will continue to study in the future. AURKA, BIRC5, CDKN3 and TYMS may be potential targets for the treatment of HBV-related HCC.

Clinical targeted drugs include sorafenib, palbociclib and Dasatinib. Sorafenib is a multi-target tyrosine kinase inhibitor that promotes apoptosis, reduces angiogenesis and inhibits tumor cell proliferation. Sorafenib is currently an effective first-line therapy in advanced HCC [42]. Studies showed that anti-CDK1 therapy enhanced the anti-tumor response of sorafenib in HCC patient derived xenograft (PDX) model, and provided a reasonable combination therapy to improve the clinical efficacy of sorafenib [43]. Similarly, in our study, we found that sorafenib inhibited BIRC5, CDK1 and CCNB1 expression. Palbociclib is a selective CDK4/6 inhibitor, which was in early stage clinical trials for advanced HCC [44]. A study indicated that palbociclib induced G2/M cell cycle arrest in HCC by down-regulating the phosphorylation of FOXM1 and its downstream target genes AURKA and CCNB1 [45]. Similarly, we found that palbociclib inhibited AURK1 BIRC5, CCNB1, CDK1, CDKN3 and TYMS expression. Dasatinib is a multi-target protein tyrosine kinase inhibitor that targets the Src kinase family and has been investigated as a targeted therapy for broad-spectrum cancer types. We found that Dasatinib inhibited the expression of AURKA and BIRC5 in HBV-related HCC. Similarly, A study showed that Dasatinib inhibited the proliferation of liver cancer cells [46].

Chemotherapy drugs, such as DNA-targeting cisplatin and doxorubicin, are widely used to treat a variety of cancers, including HCC [9]. Cisplatin cross-links and damages DNA, activates DNA damage response, and subsequently induces apoptosis of cancer cells [9, 47]. In our study, we found that cisplatin increased or decreased these 6 key targets. Similarly, studies indicated that BIRC5 played a key role in promoting cell proliferation and enhancing the sensitivity of liver cancer to chemotherapy. Therefore, inhibition of BIRCR expression in combination with cisplatin might contribute to the development of more effective therapies for liver cancer [48]. Moreover, a study indicated that CDKN3 expression was negatively correlated with tumor staging, and CDKN3 inhibition promoted hepatocellular cancer cell survival and cisplatin tolerance [49]. Doxorubicin is an anthracycline antitumor drug with advantages and a broad spectrum of efficacy [50]. When taken up by cells, Doxorubicin acts primarily through non-covalent inclusion of double-stranded DNA, thereby inhibiting DNA replication in rapidly proliferating tumors [51]. We found that Doxorubicin had an effect on 6 key targets. Similarly, studies showed that CDKN3 silencing did not significantly inhibit the proliferation of HCC, but reduced their sensitivity to Doxorubicin [52]. Furthermore, miR-26a-5p inhibited HCC cells proliferation and enhanced Doxorubicin sensitivity by inhibiting AURKA [53].

In this study, we conducted reverse enrichment of TCM according to the key targets, and analyzed the properties and effects of the drugs. The properties and functions of TCM were the important basis for its clinical application. According to the theories of meridian tropisms, zang-fu, yin and yang, and TCM therapeutic principles, TCM theory was usually summarized as four properties and five tastes, meridian tropism, etc. [25]. Our study found that the properties of TCM treatment for HBV-related liver cancer were mainly warm, followed by bitter cold. Cold herbs were associated with inflammation/immunity modulation, and warm herbs affected cell growth and proliferation, reflecting that TCM herbs were widely involved in immune and cellular processes [54, 55]. Under the framework of TCM theory, bitter cold herbs cleared away heat and removed pathogenic qi. The extracts of Scutellaria barbata and Oldenlandia diffusa (Willd.) Roxb inhibited the growth of hepatitis B virus-associated hepatocellular carcinoma by regulating circRNA expression [56]. Scutellaria barbata inhibited the expression of key genes and blocked the PI3K-AKT signaling pathway to inhibit the proliferation, and migration and induce apoptosis of liver cancer cells [57]. The warm and sweet herbs had a tonic effect, suggesting that removing deficiency and filling deficiency was the main principle of TCM in the treatment of liver cancer [58]. In addition, in our previous study, we found that the application of Wenshen prescription (composed of Yougui pill and Haoqin Qingdan decoction) achieved good efficacy in the treatment of hepatitis B-related advanced liver cancer patients. The objective tumor response rate and disease control rate in the treatment group were significantly better than those in the control group. The median survival time was 6.74 months in the treatment group and 4.85 months in the control group. The survival time of the treatment group was better than that of the control group [59]. Meridians orientation contributed to understand the direction of action of drugs. In this study, the TCM was usually liver meridian, which was more consistent with the treatment of HBV-related liver cancer, followed by lung, spleen, stomach, further indicating that the role of lung, spleen, stomach and other organs was also equally important.

Then, in this study, several small molecules of TCM were obtained. Flavonoid compounds include quercetin, hesperidin, silymarin, casticin, and so on. Some studies demonstrated that quercetin inhibited the proliferation of liver cancer cells via induction of apoptosis and cell cycle arrest. The representative component quercetin was selected for experimental verification, and it was found that quercetin inhibited the proliferation of HepG2.2.15 cells and Hep3B cells, and reduced the expression levels of CDK1. Similarly, studies showed that quercetin reduced the expressions of CDK1 [60], and inhibited the proliferation of liver cancer [61]. Terpenoids and glycosides include celastrol and ursolic acid. Celastrol inhibited the growth and induced apoptosis of human HCC by regulating the STAT3/JAK2 signaling cascade [62]. It also induced caspase-dependent apoptosis of HCC cells by inhibiting the mammalian target of rapamycin (mTOR) [63]. It was also found in experimental verification that celastrol could inhibit the proliferation of HepG2.2.15 cells and Hep3B cells at a lower concentration. Moreover, we also found that celastrol reduced CDK1 expression.

Alkaloids include cantharidin and berberine. Cantharidin inhibited the proliferation of HCC stem cells and induced cell apoptosis through G2/M phase cell cycle arrest [64]. In this study, we also found that cantharidin inhibited the proliferation of HepG2.2.15 cells and Hep3B cells, and decreased the expression levels of CDK1 and CCNB1. In this study, we focused on the study of three different types of small molecular of TCM on HBV-related HCC, and the research content in this area is relatively small. At the same time, it gives us inspiration to study the effect of newly discovered small molecular of TCM on HBV-related HCC according to the classification of small molecules. In addition, we only selected three representative small molecules for verification. All three small molecules were purchased standard drugs, not self-synthesized drugs, which affected the innovation of the research. In the future, we will continue to discover new anti-HBV-related HCC drugs and conduct chemical synthesis research.

Conclusion

In summary, this study used key targets to study the TCM treatment of HBV-related liver cancer in a reverse network pharmacology system. We found that clinical drugs including chemotherapy drugs, targeted drugs, small molecules of TCM including flavonoids, terpenoids and glycosides and alkaloids, bitter and warm as well as TCM belonging to the liver and lung meridian might be useful for the treatment of HBV-related HCC. These conclusions provided a new idea for HBV-related HCC.

Author Statement

We declared that this manuscript is original, has not been published before and is not currently being considered for publication elsewhere.

We confirm that all data were generated in-house, and no paper mill was used. All authors agree to be accountable for all aspects of work ensuring integrity and accuracy.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

HCC:

Hepatocellular carcinoma

HBV:

Hepatitis B virus

HBV-related HCC:

Hepatitis B virus-associated hepatocellular carcinoma

TCM:

Traditional Chinese medicine

GEO:

Gene expression synthesis

GEPIA:

Gene expression profile Interaction Analysis

DEGs:

Differentially expressed genes

STRING:

Search Tool for the Retrieval of Interacting Genes/Proteins

PPI:

Protein–protein interaction

TCGA:

The cancer genome atlas

GTEx:

Genotype-tissue expression

OS:

Overall survival

HR:

Hazard ratios

LIHC:

Liver hepatocellular carcinoma

BLCA:

Bladder urothelial carcinoma

BRCA:

Breast invasive carcinoma

CHOL:

Cholangiocarcinoma

COAD:

Colon adenocarcinoma

ESCA:

Esophageal carcinoma

HNSC:

Head and neck squamous cell carcinoma

KIRC:

Kidney renal clear cell carcinoma

LUAD:

Lung adenocarcinoma

LUSC:

Lung squamous cell carcinoma

STAD:

Stomach adenocarcinoma

UCEC:

Uterine corpus endometrial carcinoma

BIRC5:

Baculoviral IAP repeat-containing protein 5

CDK1:

Cyclin‑dependent kinase 1

CCNB1:

G2/mitotic-specific cyclin-B1

AURKA:

Aurora kinase A

TYMS:

Thymidylate synthase

CDKN3:

Cyclin-dependent kinase inhibitor 3

CCK-8:

Cell Counting Kit-8

References

  1. Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    Article  PubMed  Google Scholar 

  2. Ridruejo E. Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma? Expert Opin Drug Saf. 2015;14:439–51.

    Article  CAS  PubMed  Google Scholar 

  3. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;4:5–13.

    Article  Google Scholar 

  4. Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol. 2018;43:13–25.

    Article  Google Scholar 

  5. Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64:S84–101.

    Article  CAS  PubMed  Google Scholar 

  6. Davis AP, et al. Comparative toxicogenomics database (CTD): update 2021. Nucleic Acids Res. 2021;49:D1138–43.

    Article  CAS  PubMed  Google Scholar 

  7. Dan W, et al. Study on medication rules of traditional chinese medicine against antineoplastic drug-induced cardiotoxicity based on network pharmacology and data mining. Evid Based Complement Altern Med eCAM. 2020;2020:7498525. https://doi.org/10.1155/2020/7498525.

    Article  Google Scholar 

  8. Dan W, et al. Rules of Chinese herbal intervention of radiation pneumonia based on network pharmacology and data mining. Evid Based Complement Altern Med eCAM. 2022;2022:7313864. https://doi.org/10.1155/2022/7313864.

    Article  Google Scholar 

  9. Li Y, Tang T, Lee HJ, Song K. Selective anti-cancer effects of plasma-activated medium and its high efficacy with cisplatin on hepatocellular carcinoma with cancer stem cell characteristics. Int J Mol Sci. 2021;22:3956.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Wang LL, et al. Systems pharmacology-based identification of mechanisms of action of Bolbostemma paniculatum for the treatment of hepatocellular carcinoma. Med Sci Monit Int Med J Exp Clin Res. 2021;27:927624.

    Google Scholar 

  11. Man S, et al. Treatment for liver cancer: from sorafenib to natural products. Eur J Med Chem. 2021;224:5.

    Article  Google Scholar 

  12. Wu S, et al. A comprehensive review of natural products against atopic dermatitis: flavonoids, alkaloids, terpenes, glycosides and other compounds. Biomed Pharmacother. 2021;140:2.

    Article  Google Scholar 

  13. Ji Y, Yin Y, Zhang W. Integrated bioinformatic analysis identifies networks and promising biomarkers for hepatitis B virus-related hepatocellular carcinoma. Int J Genom. 2020. https://doi.org/10.1155/2020/2061024.

    Article  Google Scholar 

  14. Tang Y, Zhang Y, Hu X. Identification of potential hub genes related to diagnosis and prognosis of hepatitis B virus-related hepatocellular carcinoma via integrated bioinformatics analysis. Biomed Res Int. 2020. https://doi.org/10.1155/2020/4251761.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Fang Q, Chen H. The significance of m6A RNA methylation regulators in predicting the prognosis and clinical course of HBV-related hepatocellular carcinoma. Mol Med. 2020;26:020–00185.

    Article  Google Scholar 

  16. Barrett T, et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 2013;41:27.

    Google Scholar 

  17. Szklarczyk D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607–13.

    Article  CAS  Google Scholar 

  18. Tang Z, Li C, Kang B, Gao G, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Chandrashekar DS, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19:649–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Navani S. Manual evaluation of tissue microarrays in a high-throughput research project: the contribution of Indian surgical pathology to the Human Protein Atlas (HPA) project. Proteomics. 2016;16:1266–70.

    Article  CAS  PubMed  Google Scholar 

  21. Menyhárt O, Nagy Á, Győrffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci. 2018;5:181006.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Li Z, Lin Y, Cheng B, Zhang Q, Cai Y. Identification and analysis of potential key genes associated with hepatocellular carcinoma based on integrated bioinformatics methods. Front Genet. 2021;12:571231.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Fang S, et al. HERB: a high-throughput experiment- and reference-guided database of traditional Chinese medicine. Nucleic Acids Res. 2021;49:D1197-d1206. https://doi.org/10.1093/nar/gkaa1063.

    Article  CAS  PubMed  Google Scholar 

  24. Montasser A, et al. Transarterial chemoembolization enhances programmed death 1 and programmed death-ligand 1 expression in hepatocellular carcinoma. Histopathology. 2020;16:14317.

    Google Scholar 

  25. Xia, P. et al. Data mining-based analysis of Chinese medicinal herb formulae in chronic kidney disease treatment. Evid Based Complement Alternat Med 24 (2020).

  26. Yin X, Li J, Hao Z, Ding R, Qiao Y. A systematic study of traditional Chinese medicine treating hepatitis B virus-related hepatocellular carcinoma based on target-driven reverse network pharmacology. Front Cell Infect Microbiol. 2022;12:1188.

    Article  Google Scholar 

  27. He S, et al. A defined combination of four active principles from the Danhong injection is necessary and sufficient to accelerate EPC-mediated vascular repair and local angiogenesis. Front Pharmacol. 2019;10:1080.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Fang L, Du WW, Awan FM, Dong J, Yang BB. The circular RNA circ-Ccnb1 dissociates Ccnb1/Cdk1 complex suppressing cell invasion and tumorigenesis. Cancer Lett. 2019;459:216–26.

    Article  CAS  PubMed  Google Scholar 

  29. Li Y, et al. Significance of identifying key genes involved in HBV-related hepatocellular carcinoma for primary care surveillance of patients with cirrhosis. Genes. 2022;13:2331.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Xie B, Wang S, Jiang N, Li JJ. Cyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance. Cancer Lett. 2019;443:56–66.

    Article  CAS  PubMed  Google Scholar 

  31. Huang Y, Sramkoski RM, Jacobberger JW. The kinetics of G2 and M transitions regulated by B cyclins. PLoS ONE. 2013;8:e80861.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Cheng P, et al. Hepatitis B virus X protein (HBx) induces G2/M arrest and apoptosis through sustained activation of cyclin B1-CDK1 kinase. Oncol Rep. 2009;22:1101–7.

    CAS  PubMed  Google Scholar 

  33. Chen QF, et al. Examining the key genes and pathways in hepatocellular carcinoma development from hepatitis B virus-positive cirrhosis. Mol Med Rep. 2018;18:4940–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Li H, Zhao X, Li C, Sheng C, Bai Z. Integrated analysis of lncRNA-associated ceRNA network reveals potential biomarkers for the prognosis of hepatitis B virus-related hepatocellular carcinoma. Cancer Manag Res. 2019;11:877–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Wang B, et al. Variations in the AURKA gene: biomarkers for the development and progression of hepatocellular carcinoma. Int J Med Sci. 2018;15:170–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Chen C, et al. AURKA promotes cancer metastasis by regulating epithelial-mesenchymal transition and cancer stem cell properties in hepatocellular carcinoma. Biochem Biophys Res Commun. 2017;486:514–20.

    Article  CAS  PubMed  Google Scholar 

  37. Zhang L, et al. Screening and function analysis of hub genes and pathways in hepatocellular carcinoma via bioinformatics approaches. Cancer Biomark. 2018;22:511–21.

    Article  CAS  PubMed  Google Scholar 

  38. Bao Z, et al. Association between the functional polymorphism Ile31Phe in the AURKA gene and susceptibility of hepatocellular carcinoma in chronic hepatitis B virus carriers. Oncotarget. 2017;8:54904–12.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Cao L, et al. OCT4 increases BIRC5 and CCND1 expression and promotes cancer progression in hepatocellular carcinoma. BMC Cancer. 2013;13:1471–2407.

    Article  Google Scholar 

  40. Hao L, et al. Anti-malarial drug dihydroartemisinin downregulates the expression levels of CDK1 and CCNB1 in liver cancer. Oncol Lett. 2021;22:9.

    Article  Google Scholar 

  41. Li S, Zhao J, Lv L, Dong D. Identification and validation of TYMS as a potential biomarker for risk of metastasis development in hepatocellular carcinoma. Front Oncol. 2021;11:762821.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Tang W, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5:020–0187.

    Google Scholar 

  43. Wu CX, et al. Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma. Theranostics. 2018;8:3737–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Callegari E, et al. miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models. Mol Ther Nucleic Acids. 2022;29:538–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Lee HA, Chu KB, Moon EK, Quan FS. Histone deacetylase inhibitor-induced CDKN2B and CDKN2D contribute to G2/M cell cycle arrest incurred by oxidative stress in hepatocellular carcinoma cells via forkhead box M1 suppression. J Cancer. 2021;12:5086–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Liu C, et al. Dasatinib inhibits proliferation of liver cancer cells, but activation of Akt/mTOR compromises dasatinib as a cancer drug. Acta Biochim Biophys Sin. 2021;53:823–36.

    Article  CAS  PubMed  Google Scholar 

  47. Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol. 2001;67:93–130.

    Article  CAS  PubMed  Google Scholar 

  48. Or YY, et al. Survivin depletion inhibits tumor growth and enhances chemosensitivity in hepatocellular carcinoma. Mol Med Rep. 2014;10:2025–30.

    Article  CAS  PubMed  Google Scholar 

  49. Dai W, et al. CDKN3 expression is negatively associated with pathological tumor stage and CDKN3 inhibition promotes cell survival in hepatocellular carcinoma. Mol Med Rep. 2016;14:1509–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Liu C, Ma X, Zhuang J, Liu L, Sun C. Cardiotoxicity of doxorubicin-based cancer treatment: What is the protective cognition that phytochemicals provide us? Pharmacol Res. 2020;160:8.

    Article  Google Scholar 

  51. Agudelo D, Bourassa P, Bérubé G, Tajmir-Riahi HA. Review on the binding of anticancer drug doxorubicin with DNA and tRNA: Structural models and antitumor activity. J Photochem Photobiol B. 2016;158:274–9.

    Article  CAS  PubMed  Google Scholar 

  52. Dai W, et al. CDKN3 expression predicates poor prognosis and regulates adriamycin sensitivity in hepatocellular carcinoma in vitro. J Int Med Res. 2020;48:0300060520936879.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Yuan YL, Yu H, Mu SM, Dong YD, Li Y. MiR-26a-5p inhibits cell proliferation and enhances doxorubicin sensitivity in HCC cells via targeting AURKA. Technol Cancer Res Treat. 2019;18:1533033819851833.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Liang F, et al. Molecular network and chemical fragment-based characteristics of medicinal herbs with cold and hot properties from Chinese medicine. J Ethnopharmacol. 2013;148:770–9.

    Article  CAS  PubMed  Google Scholar 

  55. Liao X, Bu Y, Jia Q. Traditional Chinese medicine as supportive care for the management of liver cancer: past, present, and future. Genes Dis. 2019;7:370–9.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Yang PW, et al. Scutellaria barbata D.Don and Oldenlandia diffusa (Willd.) Roxb crude extracts inhibit hepatitis-B-virus-associated hepatocellular carcinoma growth through regulating circRNA expression. J Ethnopharmacol. 2021;275:14.

    Article  Google Scholar 

  57. Yang AY, Liu HL, Yang YF. Study on the mechanism of action of Scutellaria barbata on hepatocellular carcinoma based on network pharmacology and bioinformatics. Front Pharmacol. 2023;13:1072547.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Wang, Z. et al. On the core prescriptions and their mechanisms of traditional chinese medicine in Hepatitis B, liver cirrhosis, and liver cancer treatment. J Oncol 23 (2022).

  59. Liang X, Hu X. Effect of Wenshen formula on clinical efficacy and Th17/Treg balance in patients with advanced primary liver cancer associated with Hepatitis B. Lishizhen Med Mater Med Res. 2020;31:1649–51 ((in Chinese)).

    Google Scholar 

  60. Jeong JH, An JY, Kwon YT, Rhee JG, Lee YJ. Effects of low dose quercetin: cancer cell-specific inhibition of cell cycle progression. J Cell Biochem. 2009;106:73–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Zhang Q, Feng Z, Gao M, Guo L. Determining novel candidate anti-hepatocellular carcinoma drugs using interaction networks and molecular docking between drug targets and natural compounds of SiNiSan. PeerJ. 2021;16:e10745.

    Article  Google Scholar 

  62. Rajendran P, et al. Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer Prev Res. 2012;5:631–43.

    Article  CAS  Google Scholar 

  63. Shen B, Chen HB, Zhou HG, Wu MH. Celastrol induces caspase-dependent apoptosis of hepatocellular carcinoma cells by suppression of mammalian target of rapamycin. J Tradit Chin Med. 2021;41:381–9.

    PubMed  Google Scholar 

  64. Le AP, Zhang LL, Liu W, Shi YF. Cantharidin inhibits cell proliferation and induces apoptosis through G2/M phase cell cycle arrest in hepatocellular carcinoma stem cells. Oncol Rep. 2016;35:2970–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable

Funding

The present study was financially supported by the National Natural Science Foundation of China (No. 81973840 and No. 81273748); National science and Technology major projects of the 13th Five-Year Plan (2018ZX10303502); Science and Technology Program of Hebei (223777156D); Sichuan Provincial Administration of Traditional Chinese Medicine Major science and technology projects (2021XYCZ004).

Author information

Author notes

  1. Shenghao Li and Liyuan Hao Contributed equally.

Authors and Affiliations

  1. Chengdu University of Traditional Chinese Medicine, No. 37 Shi-er-qiao Road, Chengdu, 610075, Sichuan, People’s Republic of China

    Shenghao Li & Liyuan Hao

  2. Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shi-er-qiao Road, Chengdu, 610072, Sichuan, People’s Republic of China

    Shenghao Li, Liyuan Hao & Xiaoyu Hu

  3. Department of Pharmacy Department, The Fourth Hospital of Hebei Medical University, NO.12, Jian Kang Road, Shijiazhuang, 050010, Hebei, People’s Republic of China

    Luya Li

Authors
  1. Shenghao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Liyuan Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaoyu Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luya Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XH and SL designed research; SL, LH, LL and XH wrote the manuscript with contributions from all authors. All authors read and approved the initial manuscript.

Corresponding author

Correspondence to Xiaoyu Hu.

Ethics declarations

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, S., Hao, L., Hu, X. et al. A systematic study on the treatment of hepatitis B-related hepatocellular carcinoma with drugs based on bioinformatics and key target reverse network pharmacology and experimental verification. Infect Agents Cancer 18, 41 (2023). https://doi.org/10.1186/s13027-023-00520-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13027-023-00520-z

Keywords

  • Hepatitis B virus-associated hepatocellular carcinoma
  • CDK1
  • CCNB1
  • Traditional Chinese medicine
  • Quercetin
  • Celastrol
  • Cantharidin

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us